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In recent years multi-parameter flow cytometry has enabled identification of cells at major
stages in myeloid development; from pluripotent hematopoietic stem cells, through populations
with increasingly limited developmental potential (commonmyeloid progenitors and granulocyte-
macrophage progenitors), to terminally differentiated mature cells. Myeloid progenitors are het-
erogeneous, and the surfacemarkers that define transition states fromprogenitors tomature cells
are poorly characterized. Siglec-F is a surface glycoprotein frequently used in combinationwith IL-
5 receptor alpha (IL5R𝛼) for the identification ofmurine eosinophils. Here, we describe a CD11b+
Siglec-F+ IL5R𝛼−myeloid population in the bone marrow of C57BL/6 mice. The CD11b+ Siglec-
F+ IL5R𝛼− cells are retained in eosinophil deficient PHIL mice, and are not expanded upon over-
expression of IL-5, indicating that they are upstream or independent of the eosinophil lineage.We
showthese cells tohaveGMP-likedevelopmental potential in vitro and in vivo, and tobe transcrip-
tionally distinct from the classically described GMP population. The CD11b+ Siglec-F+ IL5R𝛼−
population expands in the bone marrow ofMybmutant mice, which is potentially due to negative
transcriptional regulation of Siglec-F by Myb. Lastly, we show that the role of Siglec-F may be, at
least in part, to regulate GMP viability.
K EYWORDS
eosinophil, granulocyte, hematopoiesis, Myb, neutrophil
1 INTRODUCTION
Myeloid differentiation begins from multipotential long-term and
short-term hematopoeitic stem cells, progresses in a step-wise fash-
ion to yield progenitor cells with increasingly limited developmen-
tal potential, and ends with the generation of terminally differenti-
ated cells with specialized function. The use of multicolor flow cytom-
etry has led to the description of many distinct progenitors that
have multi-, oligo-, and unipotent outputs. For example, granulocyte-
Abbreviations: Bl, peripheral blood; BM, bonemarrow; ChIP, chromatin immunoprecipitation; cMoP, commonmonocyte progenitor; CMP, commonmyeloid progenitor; cpm, counts permillion;
DE, differentially expressed; Eo, eosinophil; EoP, eosinophil-lineage committed progenitor; EPO, erythropoietin; FDR, false discovery rate; FSC, forward scatter; GMP, granulocyte-macrophage
progenitor; GSEA, gene set enrichment analysis; hi, High; IL5R𝛼, IL-5 receptor alpha (CD125); IL-5Tg, IL-5 transgenic; Int, intermediate; lin, lineage; lo, low;MDS, multidimensional scaling plot;
PerC, peritoneal cavity lavage fluid; PHIL, eosinophil-deficient strain; Spl, spleen; SSC, side scatter
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macrophage progenitors (GMPs) are capable of eventually giving
rise to mature neutrophilic and eosinophilic granulocytes and mono-
cyte/macrophages, but have lost the potential to make lymphoid,
megakaryocytic, and erythroid cells.1 More restricted progenitors
include the common monocyte progenitor (cMoP),2 the eosinophil-
lineage committed progenitor (EoP),3 and the basophil/mast cell pro-
genitor (B/MCP).4,5 The isolation of each of these progenitors has
begun to establish the developmental steps taken in the generation
of myeloid cells, and revealed some of the key transcription factors
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that control these processes, nevertheless transitional intermediates
and the surface markers that identify them during myelopoiesis are
largely undefined.
The transcription factor c-Myb is a critical regulator of
hematopoiesis. Indeed, Myb knockout mice die at E15.5 due to
severe hematopoietic defects,6 and mice harboring hypomorphic
Myb alleles (MybPlt4/Plt4 mice) have numerous hematopoietic alter-
ations, including supraphysiological platelet production and defects in
lymphoid specification.7,8 Myb regulates many key genes in myeloid
cells (neutrophil elastase, Spi1 (Pu.1), Cebpb, and Runx1)9–12 and
MybPlt4/Plt4 mice have increased granulocyte/macrophage colony
forming capacity,7 thusMyb regulates myeloid development.
Siglecs (sialic acid binding, immunoglobulin-like lectins) are a fam-
ily of cell-surface glycoproteins expressed primarily by innate immune
cells.13,14 Siglec-F and its human functional paralog Siglec-8, are key
surface markers used for the identification of eosinophils.15,16 Both
Siglec-F and Siglec-8 can be engaged with sialylated glycans (nat-
ural and synthetic) or antibodies to induce eosinophil death,17–20
although the extent to which Siglec-F-induced apoptosis controls tis-
sue eosinophilia is dependent upon the experimental model used.21
The natural tissue ligands for Siglec-F include glycan derivatives from
Muc5b, a mucin that is constitutively expressed on tracheal epithelial
cells.18 Both SiglecF andMuc5b knockout mice have enhanced allergic
eosinophilic inflammation following allergen challenge,18,22 suggest-
ing that Muc5b glycans and Siglec-F constitute a negative feedback
pathway that helps resolve eosinophilic inflammation. Siglec-F is also
expressed on alveolar and peritoneal macrophages,23,24 mast cells and
dendritic cells in the intestine,25,26 and intestinal epithelial (tuft andM)
cells,27,28 although the function of Siglec-F in these contexts is unclear.
Here, we describe a myeloid progenitor population that expresses
Siglec-F, but unlike EoPs, is IL-5-receptor alpha (IL5R𝛼) negative. We
show these progenitors to have GMP-like developmental potential in
vitro and in vivo, but to be transcriptionally distinct from canonical
GMPs. Furthermore,wedemonstrate apotential role for Siglec-F in the
regulation of GMP viability.
2 MATERIALS AND METHODS (BRIEF)
Full details are provided as supplementary methods. Summaries are
provided below:
2.1 Mouse strains
All procedures involving mice were approved by the WEHI Animal
Ethics Committee or the Institutional Animal Care and Use Commit-
tee of Northwestern University. UBC-GFPmice29 were obtained from
the Jackson Laboratory.MybPlt4 mice are described in Ref. 7. PHILmice
(C57BL/6) were provided by Drs. James and Nancy Lee.30 IL-5 trans-
genic (IL-5Tg) mice31 were backcrossed on to a C57BL/6 background.
2.2 Flow cytometry
Bone marrow (BM), spleens, blood, and peritoneal cavity lavage cells
were collected from 8–12 week old mice. Red blood cells were
removed by lysis with an ammonium chloride-based buffer. Cells
were stained with cocktails of antibodies recognizing CD11b, IL5R𝛼,
Siglec-F, B220, CD3, Ly6C, Ly6G, ST2, Lin, cKit, Sca1, Fc𝛾RII/III, CD34,
and CD45. Cells were resuspended in PBS/2% FCS, 2 mM EDTA,
1 𝜇g/ml propidium iodide (Sigma) to enable identification and exclu-
sion of dead cells. Cells were analyzed on a BD LSR Fortessa X-20 flow
cytometer (BD Biosciences).
Cell populations were defined using the following surface markers:
Eosinophils (CD11b+ Siglec-F+ IL5R𝛼IntSSCHi), CMP (Lin-cKit+ Sca1-
CD34 + Fc𝛾RII/IIILo), GMP (Lin-cKit + Sca1-CD34 + Fc𝛾RII/III+), and
EoP (Lin-cKit+ Sca1-CD34+ Fc𝛾RII/III+ IL5R𝛼+).
Flow cytometric analyses were performed with FlowJo V10 soft-
ware (FlowJo). Statistical tests and graphs were generated with Prism
(GraphPad Software).
2.3 Cytocentrifuge preparations
Sorted cellswere cytocentrifuged onto glass slides, air dried, fixedwith
100% methanol, and stained with May Grünwald’s stain (Merck) and
5% Giemsa in pH 6.8 buffered water (Merck) according to manufac-
turer’s instructions.
2.4 Colony forming assays
Cells were sorted from the BM of C57BL/6 mice. Colony assays were
performed as described in Ref. 32 and scored by viewing on a Nikon
Optiphot-2 light microscope.
2.5 In vivo developmental potential assays
BMwas flushed from13weekoldUBC-GFPmice inPBS/2%FCS, over-
laid onto 60% Percoll, and centrifuged at 400 × g for 25 min. Cells at
the interface were collected and stained for IL5R𝛼, Siglec-F, CD11b,
and CD34 expression. CD11b+ Siglec-F+ IL5R𝛼− cells were sorted,
washedwith ice-cold PBS and resuspended in ice-cold PBS.
Recipient Ly5.1 mice were irradiated (550 rad) 24 h prior to trans-
plantation. Sorted cells (25 𝜇L) were injected under the capsule of the
sinus of the spleen. A mock recipient mouse was injected with 25 𝜇l
PBS. Spleenswere collected fromrecipientmice1and3dafter surgery
and prepared for flow cytometry.
2.6 In vivo Siglec-F ligation
Mice (8–12 week old) were injected with 20 𝜇g anti-Siglec-F 9C7 anti-
body (a gift from Dr. James Paulson, The Scripps Research Institute)
or rat IgG2b isotype control antibody (LTF-2, Tonbo Biosciences), i.p,
every second day, on 4 occasions. BMwas collected 24 h after the last
injection and prepared for flow cytometry.
2.7 RNA-sequencing
Populations were sorted from the BM of 6–10 week old C57BL/6
and 6 week old MybPlt4/Plt4 mice. Total RNA was isolated using the
RNAeasy Micro Kit (Qiagen). Overall, 130–200 ng total RNA per sam-
ple was submitted to the Australian GenomeResearch Facility for high
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throughput mRNA-sequencing. Libraries (mRNA) were synthesized
using Illumina’s TruSeq Stranded mRNA protocol, and 100 bp reads
generatedwith an IlluminaHiSeq 2500 (Illumina). Two to five indepen-
dent RNA samples per cell type were sequenced. Bioinformatic analy-
ses are detailed in supplementarymethods.
3 RESULTS AND DISCUSSION
3.1 A Siglec-F+ IL5R𝜶− population is present in the
BMofwildtypemice
Siglec-F is a signature surface protein found on eosinophils that is used
in many laboratories to identify these cells. We have identified a pop-
ulation of cells that is Siglec-F+ but is IL5R𝛼− and CD11b+ (Fig. 1A).
These cells make up 0.56 ± 0.09% (mean ± SEM) of viable cells in the
BM, with very few cells falling in this gate in the peripheral blood (Bl),
spleen (Spl), or peritoneal cavity (PerC) (0.02±0.001%, 0.02±0.007%,
and0.04±0.001%, respectively) (Fig. 1AandB).As eosinophils are typ-
ically IL5R𝛼+ and are known to expand in response to IL-5, we sought
to characterize this Siglec-F+ IL5R𝛼− population further. The Siglec-
F+ IL5R𝛼− population has distinct FSC properties, being larger than
lymphocytes, eosinophils, or neutrophils (Supplementary Fig. 1A and
B), and side scatter (SSC) properties that are similar toneutrophils, that
is having lower SSC than eosinophils and higher SSC than lymphocytes
(Supplementary Fig. 1AandC).Overall, 78.5±1.6%of the cells express
CD34, and the cells are cKitInt, ST2−, Fc𝛾RII/III+ (Fig. 1C).Morphologi-
cally, these cells have nuclei that in cytocentrifuge preparations appear
ellipsoid or monocytoid, with occasional cells exhibiting nuclear seg-
mentation, indicating they are in the myeloid lineage, which is consis-
tent with the CD11b staining (Fig. 1D). Upon May Grünwald Giemsa
staining, theyhaveamoderateamountofbasophilic (purple/blue) cyto-
plasm andmorphologically resemble GMPs.
3.2 The Siglec-F+ IL5R𝜶− population is present in
PHILmice and is not expanded in IL-5Tgmice
Siglec-F+ IL5R𝛼− cells do not have scatter or morphological char-
acteristics of eosinophils, however, they do express the eosinophil
marker Siglec-F. We therefore formally tested whether Siglec-F+
IL5R𝛼− cells fall within the eosinophil lineage. PHIL mice are devoid
of eosinophils and their precursors (EoPs) due to transgenic expres-
sion of Diphtheria Toxin A from the Eosinophil Peroxidase promoter,
which becomes transcriptionally active in EoPs.30 PHIL mice retained
the Siglec-F+ IL5R𝛼− cells, and, similar to wildtype mice, there were
approximately 10-fold more Siglec-F+ IL5R𝛼− cells in the BM than
in any of the peripheral organs examined (Fig. 2A and B). Siglec-F+
IL5R𝛼− cells are therefore not EoPs, nor are they derived from an Epx-
expressing progenitor.
IL-5 is a potent stimulator of eosinophil development, and IL-5Tg
mice have marked eosinophilia and expansion of EoPs31 (Fig. 2C and
D). Consistent with their lack of IL5R𝛼 expression, Siglec-F+ IL5R𝛼−
cells were not significantly expanded in IL-5Tg mice (Fig. 2C and D).
Together these data suggest that it is unlikely that Siglec-F+ IL5R𝛼−
cells lie downstream of an IL-5-responsive precursor; rather they
are likely to lie upstream of an EoP or are of a lineage unrelated
to eosinophils.
3.3 The Siglec-F+ IL5R𝜶− population has
predominantly neutrophilic developmental potential
in vitro and in vivo
Given the morphological similarity of the Siglec-F+ IL5R𝛼− cells to
GMPs, and their surface expression of cKit, we assessed whether
sorted CD11b+ Siglec-F+ IL5R𝛼− cells had proliferative potential.
We tested the colony-forming potential of Siglec-F+ IL5R𝛼− cells
in semi-solid agar cultures with a cocktail of EPO, stem cell factor,
and IL-3, which facilitates the development of erythroid, granulocyte,
eosinophil, macrophage, megakaryocyte, and blast colonies. Siglec-F+
IL5R𝛼− and GMPs both made granulocytic, macrophage, and granu-
locyte/macrophage colonies (Fig. 3A), with the GMPs having a higher
colony output than the Siglec-F+ IL5R𝛼− population. GMPs also
generated a small number of blast and eosinophil colonieswhen plated
at this density. The Siglec-F+ IL5R𝛼− population also had the potential
to make eosinophil colonies when plated at a higher cell density
(data not shown). Sorted EoPs (95% purity) made almost exclusively
eosinophil colonies.
To examine their in vivo developmental potential, we sorted
CD11b+ Siglec-F+ IL5R𝛼− cells from the BM of GFP+mice and trans-
planted them into the spleens of irradiated Ly5.1 (GFP negative) recip-
ients. The immunophenotype and morphology of GFP+ cells in the
spleen were analyzed by flow cytometry 1 and 3 days post-surgery
(Fig. 3B). No GFP+ cells were detected in mice that were injected
with PBS alone (mock). GFP+ cells recovered from the spleens of
transplanted mice had upregulated surface IL5R𝛼 by day 1, and by
day 3 80% resembled neutrophils (IL5R𝛼+Ly6G+Ly6CIntSSCIntFSCInt,
Fig. 3C). Together, these data demonstrate that CD11b+ Siglec-
F+ IL5R𝛼− cells have GMP-like developmental potential in vitro,
and favor the production of granulocytes/neutrophils in vivo. The
loss of surface Siglec-F on transplanted cells suggests that Siglec-
F expression in GMPs is transient and subsequently suppressed
upon differentiation.
3.4 The Siglec-F+ IL5R𝜶− population is prominent
inMybmutantmice
Myb knockout mice die during early embryonic development due
to severe hematopoietic defects.6 Hypomorphic Myb mutant mice
(MybPlt4/Plt4) generated in our laboratory have increased granulo-
cyte/macrophage colony forming capacity.7 As shown in Fig. 4A and
B, MybPlt4/Plt4 mice also exhibited a striking increase in the percent-
age and numbers of CD11b + Siglec-F+ IL5R𝛼− cells in the BM. Pub-
lished ChIP analyses have shown the promoter of Siglec5 (encoding
Siglec-F) to be occupied by Myb.12 We examined the surface expres-
sion of Siglec-F on GMPs from C57BL/6 and MybPlt4/Plt4 mice (Fig. 4C
andD). GMPs have broad Siglec-F expression, which is elevated inMyb
mutant cells. These data suggest that Myb negatively regulates Siglec-
F expression, andprovides a possiblemechanism for the prominenceof
Siglec-F+GMPs inMybPlt4/Plt4 mice.
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F IGURE 1 Identification and characterization of Siglec-F+ IL5R𝜶− cells. (A) Flow cytometry dot plots showing Siglec-F and IL5R𝛼 expression
in CD11b+ viable cells in C57BL/6 bonemarrow (BM), blood (Bl), spleen, and peritoneal cavity lavage fluid (PerC). Eosinophils (Siglec-F+ IL5R𝛼Int)
and Siglec-F+ IL5R𝛼− populations are gated. The percentage of cells falling within each gate are shown. (B) Quantification of Siglec-F+ IL5R𝛼Int
(eosinophil) andCD11b+ Siglec-F+ IL5R𝛼- cells (as a percentage of viable cells) in the 4 tissues shown in (A). Note, contaminating eosinophils in the
CD11b+ Siglec-F+ IL5R𝛼− gate have been excluded from quantification on the basis of high side scatter. Data is presented as mean + SEM (n = 4
mice), with individual mouse data points shown. p-values determined by one way ANOVA (C). Light scatter and surface marker expression in the
CD11b+ Siglec-F+ IL5R𝛼− population, GMPs and EoPs. Cells in the surfacemarker histograms for the Siglec-F+ IL5R𝛼− population have been pre-
gated to exclude any contaminating eosinophils on the basis of high side scatter. Light colored histogram represents the fluorescence of unstained
BMcells. Numbers indicate the average geometricmean fluorescence for each surfacemarker from4 independentmice (D) Representative images
of sorted and cytocentrifuged populations followingMayGrünwald Giemsa staining. Tenmicrometer scale bar shown
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F IGURE 2 The Siglec-F+ IL5R𝜶− population is present in PHILmice and is not expanded in IL-5Tgmice. (A) Flow cytometry dot plots showing
Siglec-F and IL5R𝛼 expression in CD11b+ cells in bone marrow (BM), blood (Bl), spleen and peritoneal cavity lavage fluid (PerC) from eosinophil-
deficient PHIL mice. The Siglec-F+ IL5R𝛼− cell population is gated, and percentage of gated (CD11b+) cells shown. (B) Quantification of CD11b+
Siglec-F+ IL5R𝛼− cells (as a percentage of viable white blood cells) in the tissues shown in (A). p = 0.001 as determined by one-way ANOVA. (C)
Representative flow cytometry dot plots of Siglec-F and IL5R𝛼 expression in CD11b+ cells isolated from the BM of C57BL/6 and IL-5Tg mice.
The percentage of cells falling into the Siglec-F+ IL5R𝛼Int (Eosinophil) and Siglec-F+ IL5R𝛼− gates (as a percentage of CD11b+ cells) are shown. (D)
Quantificationof thenumber ofGMP, Siglec-F+ IL5R𝛼− cells, and eosinophils inBMofC57BL/6 and IL-5Tgmice.Data are presented asmean+ SEM
(N= 3 or 4). Individual mouse data points are shown. p-values were determined by an unpaired two-tailed Student’s t-test withWelch’s correction
and have been corrected for multiple comparisons using themethod of Bonferroni. N.S, not significant
3.5 Siglec-F ligation regulates Siglec-F+GMP
viability and Siglec-F internalization
As engagement of Siglec-F with antibodies can inducemodest degrees
of eosinophil death in vitro, and a decrease in the number of
eosinophils in vivo,33 we explored whether CD11b+ Siglec-F+ IL5R𝛼−
cells are affected by Siglec-F ligation. In vivo administration of the
anti-Siglec-F antibody 9C7 caused loss of surface Siglec-F expression
from CD11b+ cells in the BM, as measured by flow cytometry (Fig. 5A
and B). The eosinophil population was restored by Siglec-F intracellu-
lar staining (demonstratingSiglec-F internalization), however,CD11b+
Siglec-F+ IL5R𝛼− cells were only partially recovered with this tech-
nique (Fig. 5A and B). The additional loss of CD11b+ Siglec-F+ IL5R𝛼−
cells following anti-Siglec-F treatment could be explained by three
mechanisms: (i) death of Siglec-F+ cells, (ii) shedding or downregula-
tion of Siglec-F, and (iii) interference between 9C7 and the E50-2440
clone used for detection. Thus, while anti-Siglec-F treatment did not
lead to a statistically significant decrease in eosinophils (as determined
by intracellular staining with anti-Siglec-F), it caused a reduction in
CD11b+ Siglec-F+ IL5R𝛼− cells (p= 0.007).
In addition, we examined the effect of 9C7 on classically gated
GMPs. 9C7 treatment reduced surface Siglec-F expression and
increased internalization of Siglec-F in GMPs (Fig. 5C). We found a
small but statistically significant increase in dead Siglec-F+ GMPs fol-
lowing 9C7 treatment (Fig. 5D). Consistent with this finding, Siglec-
F+ GMPs have higher levels of Annexin-V binding (in the absence of
ligation), an event typically associated with early apoptosis (Fig. 5E).
Together, these data suggest that Siglec-F ligation can at least partially
regulate the viability of Siglec-F+GMPs.
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F IGURE 3 CD11b+ Siglec-F+ IL5R𝜶− cells predominantly develop into non-eosinophil granulocytes in vitro and in vivo. (A) In vitro colony
forming assay showing the percentage of each colony type formed when CD11b+ Siglec-F+ IL5R𝛼−, EoP and GMP populations are plated in
soft agar with stem cell factor + IL3 + EPO. The total numbers of colonies formed by each cell type are indicated. G/M indicates mixed granulo-
cyte/macrophage colonies. (B) Schematic representation of in vivo developmental potential assay (C) In vivo developmental potential assay. Top
right panels show typical staining characteristics of CD11b+ cells in bonemarrow. The positions of eosinophils (E), neutrophils (N) and the injected
CD11b + Siglec-F+ IL5R𝛼– (S) population are shown on the Siglec-F/IL5R𝛼 dot plot. Ly6C/Ly6G and FSC/SSC profiles of total CD11b+ cells are
shown. The position of neutrophils (N) in terms of Ly6G and Ly6C expression is indicated. The Ly6C/Ly6G and FSC/SSC characteristics of gated
CD11b+ Siglec-F+ IL5R𝛼− cells are also shown. Top left panel shows lack of GFP+ cells in a mock (PBS)-injected spleen, 3 days after surgery.
Third row, the identification of GFP+ cells from the spleen 1 day post injection, and the surface marker expression and scatter characteristics
of GFP+ cells. Bottom row, the identification of GFP+ cells from the spleen 3 days post injection, and the surface marker expression and scatter
characteristics of GFP+ cells. The predicted positions of the starting population (S), eosinophils (E), and neutrophils (N), based on side-by-side
staining ofWTBM (top row), are shown
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F IGURE 4 CD11b+ Siglec-F+ IL5R𝜶− cells increase in the bone marrow ofMyb mutant mice. (A) Siglec-F and IL5R𝛼 expression in CD11b+
cells from the bone marrow of C57BL/6 andMybPlt4/Plt4 mutant mice, as determined by flow cytometry. (B) Quantification of the percentage (of
viable cells) and numbers of CD11b+ Siglec-F+ IL5R𝛼− cells in C57BL/6 andMybPlt4/Plt4 BM. (C) Siglec-F expression in GMPs from representative
C57BL/6 andMybPlt4/Plt4 mice (D) Quantification of geometric mean fluorescence intensity (GMFI) of Siglec-F expression in GMPs from C57BL/6
andMybPlt4/Plt4 mice. p-values were determined by an unpaired, two-tailed Student’s t-test withWelch’s correction
3.6 The Siglec-F+ IL5R𝜶− population is
transcriptionally distinct from both classical GMPs
and EoPs
Our data suggest that Siglec-F+ IL5R𝛼− cells are a distinct subpop-
ulation with myeloid potential. Using RNA-sequencing, we profiled
gene expression in sorted populations of myeloid progenitors (CMP,
GMP, EoP), Eos, and Siglec-F+ IL5R𝛼− cells. When we compared the
transcriptional profile of each of these subsets using a multidimen-
sional scaling (MDS) plot, the Siglec-F+ IL5R𝛼− cellswere distinct from
each of the classical populations and exhibited a profile intermediate
between GMPs and EoPs (Fig. 6A). Consistent with these analyses,
clustering of the 100 most variable genes (across all samples shown in
the MDS plot) also positioned the Siglec-F+ IL5R𝛼− population most
closely to GMPs (Fig. 6B) with the detectable expression of a sub-
set of early EoP/eosinophil genes, including Prg2 and Prg3, but lacking
expression of Epx and eosinophil associated RNases.
As the Siglec-F+ IL5R𝛼− cells had GMP-like developmental poten-
tial, we examined the gene expression differences between this pop-
ulation and canonical GMPs. We found 120 genes to be significantly
upregulated in theSiglec-F+ IL5R𝛼−population (FDR<0.05);with230
genes that were downregulated in the Siglec-F+ IL5R𝛼− population,
relative toGMPs (350 genes in total, Supplementary Table 1). This con-
trastedwith the comparisonbetween the Siglec-F+ IL5R𝛼−population
and EoPs, where > 14-fold more genes were differentially expressed
(DE); 3005 genes upregulated and 2143 downregulated (Supplemen-
tary Table 2). Therefore, transcriptionally, the Siglec-F+ IL5R𝛼− cells
more closely resemble GMPs than EoPs.
Given the similarities in morphology, and transcriptional pro-
filing between GMPs and the Siglec-F+ IL5R𝛼− population, we
conducted gene ontology (GO) analyses on the 350DE genes to better
understand differences between the two populations.34,35 The most
statistically significant GO terms associated with DE genes included
‘immune_system_process’ (FDR q-value (q) = 1.21 × 10−54, 101 genes
are marked in Supplementary Table 1) and ‘immune_response’
(q = 4.32 × 10−36). Highly significant was the term ‘regula-
tion_of_cytokine_production’ (q = 4.3 × 10−23), with Csf1R, IL6R,
C3 and Tlr5, and Tlr8 among the 38DE genes captured by this category.
Having demonstrated Siglec-F+ IL5R𝛼− cells are expanded in the
MybPlt4/Plt4 mice, we performed RNAseq on this population from
MybPlt4/Plt4 mice and controls and identified 813 DE genes between
Siglec-F+ IL5R𝛼− populations fromMybPlt4/Plt4 and C57BL/6WTmice
(Supplementary Table 3). Of the 416 genes more highly expressed
in MybPlt4/Plt4 cells, 90 were involved with ‘immune_system_process’
(q= 2.22 × 10−37) and 54with ‘biological_adhesion’ (q= 2.42× 10−24).
Twelve genes associated with integrin signaling, including seven inte-
grins, were upregulated in MybPlt4/Plt4 cells, suggesting potentially
altered binding, adhesion or migratory capabilities. We examined the
DE lists for known Myb target genes (based on Myb ChIP data pro-
duced in the Snyder lab at Stanford: ENCODE data available online as
ENCSR000ETR, and data published by the Gonda lab with a truncated
Myb12) finding that 43% of genes upregulated inMybPlt4/Plt4 cells were
known Myb ChIP targets, compared to 49% of downregulated genes,
although the mechanisms underlying regulation of the population by
Myb requires further study.
We analyzed the transcription factors36 that were differentially
expressed between the Siglec-F+ IL5R𝛼− population and GMPs. Eight
transcription factors were upregulated in the Siglec-F+ IL5R𝛼− pop-
ulation (Cebpe, Mxd1, Id2, Dach1, Pml, Bcl11a, E2f2, and Ets1) and
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F IGURE 5 In vivo Siglec-F ligation with antibody affects Siglec-F+ GMP viability. C57BL/6 mice were injected i.p. with anti-siglec-F (9C7) or
isotype (control) antibodies. (A) Representative Siglec-F and IL5R𝛼 expression in 9C7 and control antibody treated mice (pre-gated CD11b+), fol-
lowing intracellular isotype staining (i.e., surface Siglec-F expression, left panels) and intracellular Siglec-F staining (right panels). (B) Quantification
of bone marrow CD11b+ Siglec-F+ IL5R𝛼− cells following 9C7 or isotype treatment and intracellular Siglec-F staining. (C) Siglec-F fluorescence
intensity in GMPs from 9C7 and control treated mice following surface (Iso) and intracellular Siglec-F staining. (D) Induction of Siglec-F+ GMP
cell death following 9C7 treatment. (E) Quantification of Annexin-V binding in untreated Siglec-F+ and Siglec-F- GMPs. p-values in (B), (D), and (E)
were determined by an unpaired, two-tailed Student’s t-test with Welch’s correction, and further correction for multiple testing. p-values in (C)
were determined by a one-way ANOVAwithmultiple testing correction using Sidak’s method
16 downregulated in the Siglec-F+ IL5R𝛼− population compared to
GMPs (including Irf5, Irf8, Nrg1, Klf4, and Ifi204). Expression of these
factors, together with a suite of transcriptional regulators known to be
important for GMP specification are shown in Fig. 6C.
We particularly noted the differential expression of the transcrip-
tion factor Irf8 (higher in GMPs than the Siglec-F+ IL5R𝛼− population)
(Fig. 6C). Olsson et al. recently described a large-scale single cell RNA-
sequencing study performed on sorted GMPs and described Irf8 and
Gfi1 as negatively correlated, concluding that Irf8hi cells were mono-
cytic precursors, and Irf8– (Gfi1hi) were specified granulocyte and bi-
potential precursors.37 Although this level of specification was not
observed in our experiments, we did observe that there was a bias
towards the formation of granulocytes by CD11b+ Siglec-F+ IL5R𝛼−
cells in our in vitro colony assays compared to GMPs. The downregula-
tion of Irf8 in the Siglec-F+ IL5R𝛼− population was concomitant with
downregulation of Klf4, Irf5, and Csf1r as would be predicted by the
Olsson et al. study (Klf4 and Irf5 shown in Fig. 6C). Drissen et al.23 also
recently performed single cell RNA-sequencing experiments reporting
heterogeneity within myeloid progenitors. Specifically, Drissen et al.
described a Gata1-positive GMP that was biased towards eosinophil
and mast cell specification, and a Gata1-negative GMP biased
towards neutrophil andmonocyte specification. Our Siglec-F+ IL5R𝛼−
population has a higher mean expression of Gata1 than GMPs but the
expressiondifference is not statistically significant and the cells are not
specified towards eosinophil generation (Fig. 6C).
In sum, we have described a GMP-like population that expresses
Siglec-F, is transcriptionally distinct fromGMPsandhas predominantly
neutrophilic granulocyte potential in cell production assays. Given the
increase in Annexin-V staining within the Siglec-F+GMP gate we pro-
pose that Siglec-F may function, at least in part, to regulate viability of
this GMP subset.
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